Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
T Cells
36%
T Cell Depletion
29%
Chimeric Antigen Receptor T-cell Therapy
26%
Adoptive Cell Therapy
23%
T Cell Targeting
16%
B-cell Malignancies
16%
Engineered T Cells
16%
CD19
15%
Acute Lymphoblastic Leukemia
13%
Chimeric Antigen Receptor Therapy
13%
Clinical Trials
13%
Cell Therapy
13%
T Cell Activation
13%
Neuroblastoma
11%
Genome Editing
11%
Tumor
10%
4-1BB
9%
Resistance Mechanisms
9%
Co-stimulatory Domain
9%
CD22
9%
Adoptive Immunotherapy
9%
Xenograft Model
9%
Antigen-independent
9%
Highly Active
9%
Leukemia
8%
Cancer Immunotherapy
7%
Hematological Malignancies
7%
CART19
7%
Solid Tumors
7%
Autologous T Cell
7%
Culture Method
6%
Ovarian Cancer
6%
Chronic Lymphocytic Leukemia
6%
Pediatric Malignancy
6%
Non-Hodgkin Lymphoma
6%
Early Memories
6%
Memory Phenotype
6%
Hematopoietic Cell Transplantation
6%
CAR Therapy
5%
Clinical Application
5%
Immune Response
5%
Response Rate
5%
Antigen-specific
5%
High Affinity
5%
CD19 chimeric Antigen Receptor T Cells
5%
Improved Outcomes
5%
Durable Remission
5%
Medicine and Dentistry
T Cell
68%
Chimeric Antigen Receptor T-Cell
54%
Chimeric Antigen Receptor
33%
Neoplasm
25%
Cell Therapy
24%
Chimeric Antigen Receptor T-Cell Immunotherapy
22%
Immunotherapy
21%
Diseases
19%
Chimeric Antigen Receptor Immunotherapy
19%
Cancer
17%
Malignant Neoplasm
17%
B Cell
17%
Ganglioneuroblastoma
15%
Acute Lymphoblastic Leukemia
13%
Clinical Trial
10%
B-Cell Chronic Lymphocytic Leukemia
7%
B-Cell Lymphoma
7%
Solid Malignant Neoplasm
7%
Pediatrics
7%
Childhood Cancer
6%
Genome Editing
6%
Cytotoxicity
6%
Hematologic Malignancy
6%
Leukemia
6%
Ovarian Cancer
6%
Cell Transplantation
6%
Hematopoietic Cell
6%
Immunity
5%
Xenograft
5%
Death Receptor
5%
Immunology and Microbiology
T Cell
47%
Chimeric Antigen Receptor T-Cell
38%
Chimeric Antigen Receptor
37%
Immunotherapy
19%
CD19
11%
B Cell
10%
CD22
9%
Chimeric Antigen Receptor T-Cell Therapy
8%
Peptides
7%
Cell Function
7%
Immunity
7%
Cytotoxicity
6%
Antigen Specificity
5%
T Cell Receptor
5%